BTL Successfully Defends EMFACE® Patent Rights Against WonderFace Device Manufacturer

BTL Successfully Defends Patent Rights for EMFACE®

The BTL Group, a global leader in medical technologies, has achieved a significant legal victory in the ongoing protection of its proprietary technology, EMFACE®. Recently, BTL announced that it successfully concluded multiple patent infringement proceedings against Lexter Microelectronic Engineering Systems S.L., the manufacturer of the competing device WonderFace. This decision underscores BTL's commitment to safeguarding its innovations and intellectual property in the cosmetic medical field.

Background of the Case

The patent infringement accusations brought against Lexter were initiated across various jurisdictions due to the unauthorized use of BTL's patented technologies which shield core aspects essential to its EMFACE® product. By leveraging radiofrequency for muscle stimulation, combined with electrical stimulation techniques, EMFACE® offers advanced facial treatments that promote skin rejuvenation and elasticity.

In a favorable turn of events, Lexter has entered into an agreement that mandates them to cease all operations related to the manufacturing, marketing, and global distribution of their device WonderFace, effectively halting any infringement of BTL’s patents going forward. This announcement signifies a crucial step for BTL and its efforts to maintain its competitive edge in a rapidly evolving industry.

Statement from BTL Leadership

Tomas Schwarz, the CEO of BTL Group, expressed his satisfaction with the outcome, stating, “This global and definitive resolution is a testament to our determination to protect BTL’s intellectual property rights and safeguard the investments of our clients.” His confidence reflects the strength of BTL’s robust patent portfolio, consisting of over 200 international patents, solidifying the company’s position as a leader in medical innovation.

About EMFACE® and Its Significance

EMFACE® is at the forefront of non-invasive aesthetic procedures, constructed around the revolutionary application of energy-based technology. The device simultaneously enhances facial muscle tone while addressing various skin concerns, making it a popular choice in clinics and beauty centers worldwide. BTL’s commitment to scientific advancement ensures that EMFACE® remains a preferred option for non-invasive facial rejuvenation treatments.

For individuals seeking more information about EMFACE®, BTL invites you to visit www.emface.com where detailed insights into the technology and treatment options are available. With BTL’s patented technologies, patients can expect the highest standards of safety and effectiveness in their aesthetic treatments.

Conclusion

As BTL continues to innovate and expand its offerings, this decisive legal victory serves as a strong reminder of the importance of intellectual property rights in fostering innovation. The successful enforcement of BTL’s patent rights not only protects its cutting-edge technologies but also reinforces the significance of trust and quality in the medical aesthetics industry. Expect further advancements from BTL that will continue to shape the future of non-invasive aesthetic treatment.